Wilms' tumour 1 gene (WT1) is highly expressed in various types of leukaemia which has advanced its position both as a target for immunotherapy and as a means of monitoring minimal residual disease (MRD). The precise role of WT1 in haematopoiesis and its contribution to leukemogenesis are open to speculation. 1 One hypothesis is that wild-type WT1 may act both as an enhancer of cellular quiescence in haematopoietic stem cells and later as an inducer of cellular differentiation in committed precursors. 2 Hence, abrogation of WT1 function could promote stem cell proliferation and induce a block in differentiation, the hallmarks of the two-step hypothesis for the development of acute myeloid leukemia (AML). Mutations in WT1 occur in 10-15% of AMLs, and a link between mutation and failure to respond to standard induction chemotherapy has been proposed. 3 In support of this study, Nyvold et al. 4 noted the emergence of a WT1 -mutated subclone following therapy suggesting that mutation of WT1 could lead to progression of leukemia by conferring drug resistance. Our group recently reported an association between acquired uniparental disomy of 11p and homozygous mutation of WT1 in a patient with normal karyotype AML. 5 As this patient was also refractory to first-line chemotherapy, we investigated the relationship between WT1 mutation and treatment outcome in patients with normal cytogenetics.
Local Research Ethics Committee approval was obtained before initiation of the study. WT1 mutation analysis was performed on DNA from a group of 70 patients with normal karyotype AML (female 38/male 32; median age at diagnosis 55.2 years, range 19-78, FAB type M1-31; M2-14, M4-14; M5-9, M6-2; 46 patients o60 years) using a polymerase chain reaction-direct sequencing approach. Intronic primers (available on request) flanking exons 2-10 were used to amplify individual exons, and resultant products were directly sequenced by the use of an ABI 377 DNA sequencer (PE Applied Biosystems, Foster City, CA, USA). Mutations were inferred from the resultant trace and confirmed by the use of TOPO TA cloning (Invitrogen Ltd, Paisley, UK) and sequence analysis of the corresponding mutated clones. Statistical analysis was per- formed using STATA 7 (STATA Corporation, College Station, TX, USA) with differences assessed using Fisher's exact test. The frequency and location of WT1 mutation observed was similar to previously published studies with a preponderance of heterozygous mutation. Eight mutations were detected in 7/70 patients (10%) (Figure 1a) . Five patients had a heterozygous mutation of WT1, one patient had two mutations, 1340ins11bp and 1572ins3bp, and one patient harboured a homozygous mutation, 1584ins16bp, of the gene. These mutations clustered to exons 7 and 9, and consisted of short regions of insertion or deletion (1-16 bp) usually resulting in frameshift mutation and either loss or disruption of the DNA-binding domain of the protein.
If these mutations overlap with primer and probe combinations, they have the potential to interfere with WT1 quantification and the calculation of MRD. 4 Using the standard real-time quantitative reverse-transcriptase polymerase chain reaction conditions described by Nyvold et al., all six mutations described for exon 7, in our group of patients, will affect primer/probe annealing and are likely to lead to a reduction in overall WT1 quantification. Hence, the effect of WT1 mutation on MRD detection may prove important although it is only in the rare cases where biallelic mutation coincides with the location of the primer/probe that complete loss of expression will be observed.
An inherited mutation of WT1 results in the development of Wilms' tumour. As these individuals are not predisposed to the development of leukemia we searched for cooperating mutations necessary for the onset of AML in our patients with sporadic WT1 mutation. A significant positive association was observed between WT1 and FLT3 mutation with 6/7 patients with WT1 mutation also having FLT3 internal tandem duplication (ITD) (P ¼ 0.01). It was notable that none of the patients having mutation of both WT1 and FLT3 mutations achieved a complete remission (CR1) with standard induction chemotherapy (n ¼ 5: one patient died before starting chemotherapy). Failure to achieve CR1 was most pronounced in the WT1-FLT3-ITD patients in comparison with patients with FLT3-ITD alone, 100% (5/5) vs 23% (4/17) (P ¼ 0.01) (Figure 1b) , suggesting that the adverse outcome may be attributed to the presence of mutated WT1 in these patients.
Normal karyotype AML represents the largest cytogenetic group of patients with AML. A better understanding of the pattern of gene mutation in this patient group will have an increasing influence on prognosis, treatment and options for MRD. 6 Although validation of our results in a larger and homogenously treated series is essential, this study along with the work of Kings-Underwood and co-workers suggests that WT1 mutation may represent a poor prognostic indicator in AML. The clustering of mutations to particular exons and the change in PCR fragment size accompanying mutation makes WT1 suitable for fluorescence-based capillary electrophoresis analysis, which has recently been adopted for screening of CEBPA, FLT3-ITD and NPM. 7, 8 This would allow the rapid selection of poorer prognostic patients suitable for experimental therapies.
